Hematology contracts signed worth EUR 4.65m

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Hematology contracts signed worth EUR 4.65m

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, announces that it has signed three new contracts in the key organic growth area of Hematology point-of-care testing, worth approximately €4.65m (c. £4.03m), to be delivered over the next 12 to 24 months.

The contracts, for the supply of hemoglobin analysers and related consumables, have been secured by EKF's distribution partners in Latin America and Africa. One contract represents a return to significant sales in Peru, following a sharp decline in local sales due to geo-political factors within the country. Another contract marks EKF's first sales into Uganda, as strong sales growth continues across Africa.

The Company successfully increased supply capacity going into H2 2025 to meet rising demand. With the order book already at record levels and now full for 2025, further investment will be deployed to grow Hemoglobin consumable and analyser production capacity at the Barleben site by 30% as part of the five-year strategic development plan for the business.

The additional contracts reinforce the Board's confidence in delivering growth at the revenue and adjusted EBITDA1 levels for FY 2025 in-line with market expectations2. The continued global expansion of EKF's Hematology analyzer footprint also provides confidence in future growth as these continue to drive the pull through of consumables.

Commenting, Gavin Jones, Chief Executive Officer, said: "As part of our five-year strategic development plan to support accelerated organic growth, we identified that Hemoglobin testing was the most significant growth opportunity within our POC portfolio. We're very pleased to see that allowing our dedicated POC sales team to focus on core growth products is bearing fruit, particularly in Hemoglobin POC testing. As we win more and more new contracts and increase our global analyser footprint, we will see the benefits not just this year, but also in the years to come as consumable pull-through drives higher margin revenue growth."

1Earnings before interest, tax, depreciation and amortisation, excluding exceptional items.

²Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2025 to be £53.6m and £12.4m respectively.

The person responsible for arranging the release of this Announcementon behalf of the Company is Gavin Jones, Chief Executive Officer.

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.